When considering theSemaglutide Weight Loss Dosage chartfor adults with Type 2 diabetes, it’s important to understand the dosing regimen. For oral tablets, the initial dose starts at 3 mg once daily for 30 days, after which it may be increased to 7 mg once daily. If additional glycemic management is required, the dose can be titrated to 14 mg once daily. The maintenance dose typically ranges between 7-14 mg daily, with a maximum recommended dose of 14 mg per day. Notably, taking two 7 mg tablets to achieve the 14 mg dose is not advised.
For subcutaneous administration, the starting dose is 0.25 mg once weekly for four weeks, followed by an increase to 0.5 mg weekly. After another four weeks at 0.5 mg, the dose may be further increased to 1 mg weekly. The maintenance dose for subcutaneous administration generally falls between 0.5-1 mg once per week, depending on the patient’s needs.
Maximum dose: 1 mg/week
When referencing the Semaglutide Weight Loss Dosage chart, it’s important to understand the guidelines for both subcutaneous administration and oral tablets. For patients taking 14 mg once daily orally, subcutaneous administration can begin after the last oral dose. Conversely, oral therapy may commence up to seven days after the last subcutaneous injection. It is important to note that an oral equivalent for the weekly subcutaneous dose of 1 mg is not recommended.
There are a few key comments to keep in mind: The 0.25 mg subcutaneous weekly dose and the 3 mg oral daily dose are intended solely for the initiation of treatment, not for long-term glycemic management. Additionally, this drug has not been studied in patients with a history of pancreatitis, so alternative antidiabetic treatments should be considered for these individuals.
Uses
Semaglutide includes improving glycemic levels in adults with type 2 diabetes mellitus as an adjunct to diet and reducing the risk of serious adverse cardiovascular events in adults with established cardiovascular disease and type 2 diabetes.
Usual Adult Dose for Cardiovascular Risk Reduction
Oral Tablets: Initial dose: 3 mg once daily for 30 days, then 7 mg once daily
Titration: If you need additional glycemic management after taking 7 mg/day orally for 30 days, increase the dose to 14 mg once daily.
Maintenance dose: 7-14 mg orally, once daily
Maximum dose: 14mg/day. (Taking two 7mg tablets in order to get a dose of 14mg is not recommended.
Subcutaneous Administration:
Initial dose: 0.25mg subcutaneously, once per week for four weeks. Then 0.5mg subcutaneously every week.
After 4 weeks of receiving a 0.5 mg subcutaneous dose once a day, you may consider increasing to 1 mg once a day.
Maintenance dose: Subcutaneously 0.5-1 mg once per week
Maximum dose: 1 mg/week
Subcutaneous administration and oral tablets:
Subcutaneous administration can begin after the last oral dose for patients receiving 14 mg once daily.
Oral therapy can begin up to seven days after the last subcutaneous injection.
It is not recommended that an oral equivalent of a weekly subcutaneous dose 1 mg be used instead
Comments:
The doses of 0.25mg subcutaneously every week and 3mg orally once daily are for the initiation of treatment and not for glycemic management.
The drug has not yet been studied on patients who have a history pancreatitis. Other antidiabetic treatments should be considered for these patients.
Uses:
To improve the glycemic level in adults with type 2 Diabetes mellitus, as an adjunct to diet.
Reduce the risk of serious adverse cardiovascular events in adults with established cardiovascular disease and type 2 diabetes.
Use The Usual Adult Dose For Weight Loss
When following the Semaglutide Weight Loss Dosage chart, it’s essential to adhere to the recommended initial dose escalation schedule. For weight loss, the usual adult dose begins with:
Weeks 1 to 4: 0.25 mg subcutaneously, once per week
Weeks 5 to 8: 0.5 mg subcutaneously, once per week
Weeks 9 to 12: 1 mg subcutaneously, once per week
Weeks 13 to 16: 1.7 mg subcutaneously, once per week
For maintenance:
Weeks 17 and beyond: 2.4 mg once per week subcutaneously
Considerations for Dosing:
If you experience difficulty tolerating the dose, consider delaying escalation by 4 weeks.
If the 2.4 mg maintenance dose is not tolerated, it can be temporarily reduced to 1.7 mg weekly for up to 4 weeks. After 4 weeks, attempt to increase back to 2.4 mg weekly; if the patient still cannot tolerate 2.4 mg, treatment should be discontinued.
Comments:
Blood glucose levels in patients with type 2 diabetes should be monitored both at the beginning and throughout treatment.
The safety and efficacy of using this drug in conjunction with other weight-loss products are not known.
It has not been studied in patients with a history of pancreatitis.
Uses: This medication is indicated for managing chronic weight in adults with a BMI of 30 kg/m² or higher, or in those with at least one weight-related comorbid condition, such as type 2 diabetes, hypertension, or dyslipidemia.
When referencing the Semaglutide Weight Loss Dosage chart, it’s important to keep in mind the following dose adjustments and precautions:
Renal Dose Adjustments:
No adjustment recommended.
Liver Dose Adjustments:
No adjustment recommended.
Dose Adjustments:
The risk of hypoglycemia is increased when this medication is used concurrently with insulin or an insulin secretagogue, such as sulfonylurea. This includes the risk of severe hypoglycemia. It may be necessary to reduce the dose of insulin or insulin secretagogue accordingly.
Precautions:
US BOXED WARNING - Risk of Thyroid Cell Tumors:
This drug has been shown to induce thyroid C-cell tumors in rodents when exposed to clinically relevant doses and durations. However, the relevance to humans is unknown, and it is uncertain whether this drug causes thyroid cancers, including medullary thyroid carcinoma (MTC), in humans.
The drug is contraindicated for patients with a family or personal history of MTC and those with Multiple Endocrine Neoplasia Syndrome type 2 (MEN 2).
Patients should be informed of the risks of MTC and the symptoms of thyroid cancer, such as a mass on the neck, difficulty swallowing (dysphagia), or shortness of breath (dyspnea). The value of routine monitoring of serum calcium or thyroid ultrasound for the early detection of MTC in patients taking this drug remains uncertain.
CONTRAINDICATIONS:
Semaglutide or any of its excipients has caused a serious hypersensitivity reaction in the past;
Subcutaneous formulations have been associated with hypersensitivity reactions, including anaphylaxis.
Hypersensitivity to any active substance or product component (oral formulation).
Family or personal history of medullary Thyroid Carcinoma (MTC).
Patients with Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2)
Patients younger than 18 have not yet been evaluated for safety and efficacy.
For additional precautions, please refer to the WARNINGS section.
Dialysis
There is no data available on dialysis.
Other Comments
Advice on administration: Oral Tablets
This drug will be absorbed more quickly if taken with plain water. If you take this medication with other beverages or food than water, the absorption may be reduced.
Do not crush, split or chew the tablet.
It is not recommended to take two 7mg tablets in order to get a dose of 14mg
MISSED DOSAGE: Skip the missed dose if you have missed a dose. Continue with your regular schedule.
Subcutaneous Injection:
Subcutaneously inject once a week in the upper arm, thigh or abdomen. Use a new injection site every week if you are injecting the same body area.
Give at any time during the day; with or without food.
If you are administering insulin, it is best to administer separate injections. It's okay to administer in the same area, but the injections shouldn't be adjacent.
Do not share a pen, even if it has a new needle. Do not share needles and syringes with other patients, as this can lead to the transmission of bloodborne pathogens.
MISSED DOSAGE for Type 2 Diabetes:
If you miss a dose, give it as soon as possible, but no later than 5 days. If more than 5 have passed, give the dose the following day.
The day of the weekly administration can be changed, as long as there is a time interval between doses greater than 48hours
MISSED DOSE for WEIGHT LOSS
If a dose is missed, and the next dose is scheduled to be administered in more than 48 hours (more than 2 days), administer it as soon as you can.
Do not administer a dose if the next scheduled dosage is within 48 hours of the missed dose. Dosing will resume on the regular scheduled day of each week
If you miss more than two consecutive doses, restart the treatment as per the schedule or follow the dose-escalation plan. This may help reduce gastrointestinal symptoms that are associated with the reinitiation.
Storage requirements
Oral:
Store tablets in the original blister card to protect them from moisture. Store in a dry place, away from moisture.
Parenteral:
OZEMPIC: (Indication for type 2 diabetes): Before first use, store at room temperature or in the refrigerator (59F to 85F; 15C-30C); use within 56days.
Wegovy (weight loss indicator): Before first use, refrigerate (36F-46F, 2C-8C); do NOT freeze, and do not use frozen product. If necessary, before removing the cap, you may store it at 8C-30C (46F-86F), for up to 28days.
Store pen without the needle.
Protect your pen from heat and sun by securing the cap when not in usage.
Reconstitution/preparation techniques: Patients should receive proper training from their healthcare provider prior to first use. You can find detailed instructions on the product label.
Prefilled dial-a dose pen: Use disposable needles of up to 8mm in length. Each injection should be given with a different needle.
Compatible: Do not combine with other products.
General:
Clinical trials have shown that this drug reduces blood glucose levels after eating and fasting.
Patients with a pancreatitis history should consider other treatments.
Semaglutide was consistently effective in reducing major adverse cardiovascular events in the SUSTAIN and PIONEER trials, compared to comparators, across subgroups with varying cardiovascular risks. However, there was no effect observed in patients who had prior heart failure.
The drug is not effective for treating patients with type 1 diabetic mellitus, or diabetic ketoacidosis.
When using the Semaglutide Weight Loss Dosage chart, thorough monitoring and patient guidance are essential to ensure safety and effectiveness.
Monitoring:
Patients with type 2 diabetes taking this medication should have their blood glucose levels measured at baseline and throughout treatment.
Monitor renal function, especially if patients experience severe gastrointestinal symptoms.
Regularly monitor heart rate.
Be vigilant for signs and symptoms of pancreatitis.
Keep an eye on the progression of diabetic retinal disease.
Watch for symptoms of thyroid cancer, such as a mass in the neck or throat, dysphagia, dyspnea, or persistent hoarseness.
Monitor patients for any suicidal thoughts and behaviors while taking this weight loss drug.
Patient Advice:
Patients should read the FDA-approved patient labeling (Medication Guide & Instructions for Use).
Advise patients receiving subcutaneous treatment not to share a pen, even if a new needle is used, as sharing needles and syringes can transmit bloodborne pathogens.
Patients should report symptoms such as persistent hoarseness or dysphagia and any changes in vision.
Inform patients about the potential for gastrointestinal (GI) adverse reactions, and the importance of avoiding dehydration. They should seek medical help if they feel dehydrated or if their GI symptoms are persistent and severe.
If pancreatitis is suspected, patients should be informed of the possibility, discontinue treatment immediately, and contact their healthcare provider.
Patients with diabetes should be aware of the signs and symptoms of low blood sugar and how to manage it. They should take extra precautions when driving or using machinery to prevent hypoglycemia.
If a patient is pregnant or planning to become pregnant, they should consult with their healthcare provider regarding potential risks to the fetus.
.png)
